Sarcoma, Ewings sarcoma, synovial sarcoma, well differentiated liposarcoma/de-differentiated liposarcomas, myxoid liposarcoma, alveolar rhabdomyosarcoma, endometrial stromal tumours, nodular fascitis, aneurysmal bone cysts, low-grade fibromyxoid sarcomas, sclerosing epitheliod sarcomas, extra-skeletal chondrosarcomas, clear cell sarcomas, desmoplastic small round cell tumour, alveolar soft part sarcoma ,EWSR1, DDIT3, SS18, MDM2, JAZ1, USP6, FUS, NR4A3, TFE3, FOXO1
PURPOSE OF PROGRAMME:
Testing for the detection of recurrent abnormalities associated with sarcomas in FFPE.
MATERIAL PROVIDED: FFPE (Formalin Fixed Paraffin Embedded sections)
DISTRIBUTIONS PER YEAR: 1
SAMPLES PER DISTRIBUTION: 3
FREQUENCY OF DISTRIBUTION: 1 distribution in accordance with the annual EQA timetable in 2017. Offered in collaboration with UK NEQAS for Molecular Genetics.
PROGRAMME OF ANALYSIS:
FFPE samples for three cases are sent to the laboratory, each with a referral card to mimic a routine diagnostic case. Instructions and a user guide are available on the website. The participant analyses the sample, interprets the results and reports via the CEQAS website. The EQA is open for 5 weeks. Results can be entered at any time during this period. Any non-submitting labs will be contacted and given 24 hours to submit a late result.
All EQA cases are validated prior to release. Results are assessed by a panel of experts against set marking criteria based upon professional guidelines. There are three marking categories, Analytical, Interpretation and Clerical Accuracy. Each category carries two points. Deductions are made in accordance with the severity of the omission. A “critical error” is an error made in either the analytical or interpretive category that could lead to serious clinical consequences or imply a significa
Satisfactory/Poor. A non-submission is also given a poor performance.
PERSISTENT POOR PERFORMANCE:
This is defined as: a) Two poor performances in any oncology EQA in which the laboratory participates, over three or more distributions of material, within a 36 month rolling period; b) A poor performance within one year following a previous persistent poor performance designation.
From 1st January 2018, Cytogenomics External Quality Assessment Service (CEQAS) and UK National External Quality Assessment Service (UK NEQAS) for Molecular Genetics merged to become Genomics Quality Assessment (GenQA). Please click here for an overview of GenQA